Roivant Sciences (ROIV) Current Leases (2021 - 2026)
Roivant Sciences' (ROIV) quarterly Current Leases came in at $11.1 million in Q1 2026, up 13.26% YoY from $9.8 million in Q1 2025, and up 6.81% on a QoQ basis from $10.4 million in Q4 2025.
Roivant Sciences (ROIV) Current Leases (2021 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Current Leases data on file, last reported at $11.1 million in Q1 2026.
- Quarterly Current Leases rose 13.26% year-over-year to $11.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.1 million (up 13.26% YoY) and the FY2026 annual result came in at $11.1 million, up 13.26% from the prior year.
- Current Leases advanced to $11.1 million in Q1 2026, from $10.4 million in the prior quarter.
- In the past five years, Current Leases ranged from a high of $11.9 million in Q4 2022 to a low of $9.0 million in Q1 2024.
- A 5-year average of $10.5 million and a median of $10.5 million in 2023 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2024 — Current Leases declined 23.32% — and 2026, when it gained 13.26%.
- Tracing ROIV's Current Leases over 5 years: stood at $11.9 million in 2022, then retreated by 11.68% to $10.5 million in 2023, then declined by 6.13% to $9.8 million in 2024, then rose by 6.11% to $10.4 million in 2025, then climbed by 6.81% to $11.1 million in 2026.
- The last three Current Leases figures came in at $11.1 million (Q1 2026), $10.4 million (Q4 2025), and $9.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 12.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.38 Mn |
| Mar 31, 2026 | 11.15 Mn |
| Dec 31, 2025 | 10.44 Mn |
| Sep 30, 2025 | 9.00 Mn |
| Jun 30, 2025 | 9.40 Mn |
| Mar 31, 2025 | 9.84 Mn |
| Dec 31, 2024 | 9.84 Mn |
| Sep 30, 2024 | 9.52 Mn |
| Jun 30, 2024 | 9.49 Mn |
| Mar 31, 2024 | 8.97 Mn |
| Dec 31, 2023 | 10.48 Mn |
| Sep 30, 2023 | 10.90 Mn |
| Jun 30, 2023 | 11.35 Mn |
| Mar 31, 2023 | 11.69 Mn |
| Dec 31, 2022 | 11.86 Mn |
| Sep 30, 2022 | 11.40 Mn |
| Jun 30, 2022 | 11.86 Mn |
| Mar 31, 2022 | 11.40 Mn |
| Dec 31, 2021 | 11.24 Mn |
| Sep 30, 2021 | 11.52 Mn |